Trials / Conditions / Myeloproliferative Syndrome

Myeloproliferative Syndrome

11 registered clinical trials studyying Myeloproliferative Syndrome — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684	University Hospital, Clermont-Ferrand	Phase 2
Suspended	Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122	David Wald	Phase 1
Completed	Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm NCT04992949	French Innovative Leukemia Organisation	Phase 2
Recruiting	Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens Fro NCT04968834	Dana-Farber Cancer Institute	—
Recruiting	Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Red NCT03852407	University of Liege	Phase 2
Completed	The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase NCT03907436	University of California, Irvine	N/A
Recruiting	Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and S NCT02508038	University of Wisconsin, Madison	Phase 1
Completed	Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS) NCT02873832	Centre Hospitalier Universitaire Dijon	—
Completed	Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582	Case Comprehensive Cancer Center	Phase 1
Completed	Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell NCT01660607	Stanford University	Phase 1 / Phase 2
Completed	Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecu NCT05825326	Sociedad de Lucha Contra el Cáncer del Ecuador	—